Trial Profile
Predictive factor for response to intravitreal aflibercept in treatment-naïve patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 02 Feb 2018 New trial record
- 01 Jan 2018 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology